scholarly journals Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer

2020 ◽  
Vol 8 (5) ◽  
pp. 609-617
Author(s):  
Nitya Nair ◽  
Shih-Yu Chen ◽  
Ed Lemmens ◽  
Serena Chang ◽  
Dung T. Le ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Single Cell ◽  
Phase Ii ◽  
Metastatic Pancreatic Cancer ◽  
Randomized Studies ◽  
Immune Competency

scholarly journals A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer

2011 ◽  
Vol 30 (3) ◽  
pp. 1175-1183 ◽  
Author(s):  
A. B. El-Khoueiry ◽  
R. K. Ramanathan ◽  
D. Y. Yang ◽  
W. Zhang ◽  
S. Shibata ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Metastatic Pancreatic Cancer ◽  
Randomized Phase Ii

Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2021 ◽  
pp. clincanres.1789.2021
Author(s):  
E. Gabriela Chiorean ◽  
Katherine A Guthrie ◽  
Philip A Philip ◽  
Elizabeth M. Swisher ◽  
Florencia Jalikis ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Parp Inhibitor ◽  
Metastatic Pancreatic Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Randomized Phase Ii

Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer

2012 ◽  
Vol 28 (7) ◽  
pp. 597-604 ◽  
Author(s):  
Takeshi Ishikawa ◽  
Satoshi Kokura ◽  
Naoyuki Sakamoto ◽  
Takashi Ando ◽  
Eiko Imamoto ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Metastatic Pancreatic Cancer ◽  
Regional Hyperthermia

scholarly journals Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)

2016 ◽  
Vol 27 ◽  
pp. vi233 ◽  
Author(s):  
S. Bozzarelli ◽  
L. Rimassa ◽  
L. Giordano ◽  
S. Sala ◽  
M.C. Tronconi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Pancreatic Cancer ◽  
Open Label ◽  
Open Label Phase

First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study

2009 ◽  
Vol 96 (5) ◽  
pp. e18-e22 ◽  
Author(s):  
P. Afchain ◽  
B. Chibaudel ◽  
G. Lledo ◽  
F. Selle ◽  
L. Bengrine-Lefevre ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Pancreatic Cancer ◽  
First Line ◽  
Randomized Phase Ii

Phase II Study of Gemcitabine Combined with Uracil-Tegafur in Metastatic Pancreatic Cancer

Oncology ◽  
2004 ◽  
Vol 66 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Jeeyun Lee ◽  
Joon Oh Park ◽  
Won Seog Kim ◽  
Soon Il Lee ◽  
Seo Young Song ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Pancreatic Cancer

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

2008 ◽  
Vol 63 (2) ◽  
pp. 313-319 ◽  
Author(s):  
Chigusa Morizane ◽  
Takuji Okusaka ◽  
Junji Furuse ◽  
Hiroshi Ishii ◽  
Hideki Ueno ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Pancreatic Cancer ◽  
Gemcitabine Refractory
Sign in / Sign up

Export Citation Format

Share Document